Zacks Investment Research
10 Jul 2026, 10:36 UTC · 2h ago
BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
10 Jul 2026, 10:36 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
AstraZeneca's phase III CARDIO-TTRansform study for Wainua failed to meet its primary endpoint in treating ATTR-CM. — Failure of a late-stage clinical trial for a major pharmaceutical company is a significant negative event for the specific drug's commercial prospects.
-0.60BridgeBio Pharma's drug Attruby is expected to see a strengthened competitive position following AstraZeneca's trial failure. — The removal of a potential rival in a rare disease market increases the projected market share and revenue potential for the remaining competitor.
+0.50BridgeBio Pharma is expected to report revenue growth of 100.1% year-over-year in its upcoming quarterly report. — Rapid revenue growth is a strong fundamental signal, though partially offset by the expected quarterly loss.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company's phase III CARDIO-TTRansform study failed to meet its primary endpoint.
Shares soared 15.1% following a competitor's failed clinical trial, strengthening the competitive position of its drug Attruby.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
17h ago
